(RRMS) (RRMS) News Today → Will this $2 AI stock double overnight? (From Behind the Markets) (Ad) Free RRMS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineGranite Telecommunications Boosts EPIK Solution with Strategic Rapid Response Monitoring Alliancefinance.yahoo.com - April 10 at 1:31 PMPolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximabmarkets.businessinsider.com - April 4 at 3:51 AMHow Everclear’s Art Alexakis combines rock and comedy to fight MSmsn.com - March 27 at 3:31 PMWhen Does SPMS Begin?msn.com - March 26 at 12:47 AMSetPoint joins FDA’s TAP programme with MS devicemsn.com - March 22 at 9:08 PMUnveiling Atlanta's Culinary Gems with Mike Jordan and Max Hinesmsn.com - March 15 at 9:34 PMSetPoint wins second FDA breakthrough device nod for neurostim devicemsn.com - March 14 at 11:54 PMExplainer-What is bitcoin's 'halving', and does it matter?sg.finance.yahoo.com - March 13 at 4:15 PMSetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosisfinance.yahoo.com - March 13 at 9:34 AMPolTREG S.A.: PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Polandfinanznachrichten.de - March 11 at 9:59 AMPolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Polandmarkets.businessinsider.com - March 11 at 9:59 AMEMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefitsfinance.yahoo.com - February 29 at 10:15 AMIndia gets breakthrough multiple sclerosis drug, but could be unaffordable to many at Rs 10+ lakh a yrmsn.com - February 28 at 8:59 AMMultiple sclerosis: SPMS vs. RRMS explainedmsn.com - February 27 at 7:40 PMOM1 to Present Research on Multiple Sclerosis at ACTRIMS Forum 2024finance.yahoo.com - February 27 at 9:38 AMChampioning Justice: Unveiling the Impact of Gideon's Promise at "Igniting Change" Eventmsn.com - February 23 at 3:29 PMPolTREG appoints Dan Shelly as Chief Business Development Officertmcnet.com - February 21 at 2:41 PMKadarius Toney trade regrade: Who won between Chiefs, Giants after WR's Super Bowl scratchmsn.com - February 12 at 4:06 PMBlack and Hispanic Women With Multiple Sclerosis Are More Likely to Have Complicated Pregnanciesmsn.com - February 1 at 10:11 AMSandoz Group: Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germanyfinanznachrichten.de - January 31 at 3:42 AMSandoz launches biosimilar for multiple sclerosis in Germanymsn.com - January 31 at 3:42 AMSandoz To Launch Tyruko Biosimilar For Multiple Sclerosis In Germany On Feb. 1markets.businessinsider.com - January 31 at 3:42 AMSandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germanyfinancialpost.com - January 31 at 3:08 AMPolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapymarkets.businessinsider.com - January 30 at 2:19 AMPolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetestmcnet.com - January 16 at 10:30 AMTG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestonesmarkets.businessinsider.com - January 10 at 9:40 AMSteps to Getting an MS Diagnosisyahoo.com - January 8 at 7:32 PMSymptoms of MS and Unique Effects in Womenmsn.com - December 16 at 9:59 AMStriking Dundee photography exhibition showcases life with multiple sclerosismsn.com - December 6 at 8:39 AMYoung mum's heartbreaking wish after being diagnosed with MSau.news.yahoo.com - November 20 at 12:26 AMImmunic unveils data from RRMS therapy trialmsn.com - October 13 at 2:41 PMJamie-Lynn Sigler on Her MS: ‘I Pushed My Feelings Away for a Long Time’msn.com - September 28 at 6:43 PMCNN anchor John King shares rare, candid update on private 15-year MS battlemsn.com - September 28 at 6:43 PMCNN's John King Opens Up About His Multiple Sclerosis Diagnosis: 'I'm a Very Lucky Man'msn.com - September 27 at 7:22 PMaHSCT Beneficial for Most Patients With Relapsing-Remitting MSomaha.com - September 26 at 4:01 PMSandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europefinance.yahoo.com - September 26 at 9:42 AMSandoz: Biosimilar Tyruko Gets Approval In Europe To Treat Multiple Sclerosisnasdaq.com - September 26 at 9:42 AMImcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosisfinance.yahoo.com - September 13 at 10:35 AMAnokion Announces Clinical Progress with KAN-101 and ANK-700businesswire.com - September 12 at 6:47 PMSandoz partners with Samsung Bioepis to license Stelara biosimilarmsn.com - September 11 at 4:45 PMInfamous California kidnap hoaxer Sherri Papini released from prisonsfgate.com - August 27 at 1:29 PMSandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosisfinance.yahoo.com - August 25 at 6:28 AMFatigue Can Plague People With MS. Exercise May Helpusnews.com - August 9 at 7:59 AMSandoz Obtains Positive CHMP Opinion For Multiple Sclerosis Biosimilar Natalizumabnasdaq.com - July 24 at 8:55 AMSandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumabbenzinga.com - July 24 at 8:55 AMPositive Phase III results for Roche's OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosisbenzinga.com - July 13 at 5:03 AM‘I finally have power’: Meet the MS sufferers who believe a strict diet has kept them in remissionmsn.com - June 16 at 8:22 AM‘Multiple Sclerosis Doesn’t Discriminate’: Jeannie Mai Jenkins Is Advocating for Better MS Awareness in Her Communitymsn.com - June 9 at 8:39 PMWife of ‘El Chapo,’ imprisoned for helping run husband’s drug empire, transferred from federal prison to halfway housemsn.com - June 8 at 3:07 PMGroom who uses wheelchair has year of physiotherapy to stand for his first dancemsn.com - June 5 at 5:03 PM Get (RRMS) News Delivered to You Automatically Sign up to receive the latest news and ratings for RRMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Will this $2 AI stock double overnight? (Ad)It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share! Click here to learn more >>> RRMS Media Mentions By Week RRMS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RRMS News Sentiment▼0.000.52▲Average News Sentiment RRMS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RRMS Articles This Week▼01▲RRMS Articles Average Week Get (RRMS) News Delivered to You Automatically Sign up to receive the latest news and ratings for RRMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:RRMS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (RRMS) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
